MAM
Mankind Pharma highlights rising kidney disease risk on World Kidney Day
Nearly 138 million Indians live with CKD as experts urge early screening.
MUMBAI: Your kidneys rarely make noise when something is wrong. That silence, doctors say, is precisely the problem. Marking World Kidney Day, Mankind Pharma has joined healthcare experts to raise awareness about the growing burden of Chronic Kidney Disease (CKD), a condition that often progresses unnoticed until it reaches advanced stages. Globally, CKD affects nearly 10 percent of the population. In India, the scale is even more alarming. Health studies estimate that about 138 million people in the country are living with some form of chronic kidney disease, placing India among the nations with the highest disease burden worldwide.
The difficulty lies in detection. Kidneys quietly perform essential tasks such as filtering waste, balancing body fluids, regulating blood pressure and supporting several metabolic functions. Yet experts warn that an individual can lose up to 90 percent of kidney function without obvious symptoms, making routine screening crucial.
As part of its awareness initiative, Mankind Pharma is encouraging people to monitor key health indicators including blood pressure, blood sugar and kidney function through basic diagnostic tests. The campaign also features educational outreach and discussions with medical experts to highlight the importance of early detection.
The healthcare challenge extends beyond diagnosis to treatment. India requires nearly 200,000 kidney transplants every year, but only around 13,500 procedures are performed annually, meeting less than 6 percent of the total demand. The shortage of organ donors remains a major hurdle, with the country’s organ donation rate still below one donor per million population, far lower than many developed nations.
Doctors also point to lifestyle and health trends driving the surge in kidney disease. Rising rates of diabetes and hypertension remain among the leading causes, alongside factors such as high salt consumption, unhealthy diets and sedentary lifestyles.
Max Super Speciality Hospital chairman of Urology, Renal transplant and robotics Anant Kumar stressed that routine health checks can significantly reduce long term risks.
“Chronic kidney disease often progresses silently and remains undetected until it reaches advanced stages. Individuals with diabetes, high blood pressure, obesity or a family history of kidney disease should undergo regular screening through tests such as blood creatinine, urine analysis and blood pressure monitoring. Early diagnosis plays a crucial role in slowing disease progression and improving outcomes,” he said.
Mankind Pharma chief operating officer Arjun Juneja added that awareness and prevention remain key to tackling the growing health challenge.
“World Kidney Day is an important reminder that prevention and early detection are critical in addressing kidney disease. By promoting regular screenings, healthier lifestyle choices and greater awareness, we hope to encourage individuals to take proactive steps to protect their long term health,” he said.
Medical experts recommend several simple steps to protect kidney health. These include staying physically active, maintaining healthy blood sugar levels, monitoring blood pressure regularly, following a balanced diet with controlled salt intake, staying hydrated and avoiding unnecessary use of painkillers. Routine kidney function tests are especially important for people considered at higher risk.
As the global and national burden of CKD continues to rise, health professionals say awareness campaigns like World Kidney Day serve as an important opportunity to remind people that kidney health often depends on catching problems before the body shows any warning signs.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
